Share on Facebook Share on Twitter Email
Answers.com

hemolytic anemia

 

n.
Anemia resulting from the lysis of red blood cells, as in response to certain toxic or infectious agents and in certain inherited blood disorders.


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Gale Encyclopedia of Cancer:

Hemolytic Anemia

Top

Key Terms: Erythrocytes, Erythropoietin, Hemolysis, Spherocytosis, Stem cells.

Description

Red blood cells (erythrocytes) transport oxygen and carbon dioxide in the bloodstream, maintain a normal acid-base balance, and determine how thick or thin the blood is. Hemolytic anemia refers to the premature, increased destruction of erythrocytes. Hemolysis is the rupture of these erythrocytes with the release of hemoglobin into the plasma, and anemia is a reduced delivery of oxygen to the tissues. Some of the symptoms of hemolytic anemia include nosebleeds, bleeding gums, shortness of breath, fatigue, rapid heartbeat, pale skin color or yellow skin color (jaundice), chills, and dark-colored urine.

Causes

Erythrocyte (red blood cell) formation takes place in the red bone marrow in an adult and in the liver, spleen, and bone marrow of the fetus. Their formation requires an adequate supply of iron, cobalt, copper, amino acids, and certain vitamins. When the bone marrow loses its ability to compensate for the destruction of the erythrocytes by increasing their production, hemolytic anemia occurs. There are many types of hemolytic anemia, which are classified according to the location of this inability to produce red blood cells. If the problem lies within the red blood cell itself, it is referred to as an intrinsic factor, and if the problem is outside the red blood cell, it is referred to as an extrinsic factor. The overall incidence of hemolytic anemia is approximately 4 per 100,000 people.

Rh factor incompatibility refers to genetically determined substances capable of producing an immune response (antigens). This can cause hemolytic anemia not only during pregnancy when the mother is Rh negative and the fetus is Rh positive, but in mismatched blood transfusions as well. There are a number of industrial poisons that produce hemolytic anemia. These include:

  • antimalarial agents
  • organic solvents (benzene)
  • certain chemotherapies
  • hypersensitivity to certain antibiotics
  • metals (chromium, platinum salts, nickel, lead, copper)
  • Pyridium
  • arsenic
  • intravenous (IV) water (an IV that is not normal or half-normal saline)
  • snake bites (if the venom contains hemolytic toxins) These are all factors external to the red blood cell and thus are extrinsic in nature.

One important extrinsic factor in the cause of hemolytic anemia is in the course of widespread cancer, leukemia, Hodgkin's disease, acute alcoholism and liver disease. Many of the chemotherapy agents (cisplatin, carboplatin and nonplatinum drugs) utilized in treating various cancers have side effects that cause a suppression of bone marrow activity, which results in severe hemolytic anemia. In essence, an individual is not only anemic as a result of cancer, but this anemia is worsened by the treatment. Since nausea, vomiting, and lack of appetite are also side effects of chemotherapy, it is extremely difficult for the patient to overcome this anemia with diet and supplements. Eventually, severe hemolytic anemia is the end result.

Intrinsic factors would include disorders in the immune response and genetically inherited disorders such as glucose-6-phosphate dehydrogenase deficiency, an essential enzyme. People with this disorder do not display any symptoms until exposed to certain medications or stress. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) can precipitate this reaction. This disorder is more common among African-American males, with approximately 10% to 14% of the population being affected. Other genetic disorders include sickle cell anemia, thalassemia, and spherocytosis. All of these produce structurally abnormal red blood cells to varying degrees.

Treatments

The treatment depends upon the cause and severity of the anemia. Medicines like folic acid and corticosteroids may be used to treat the anemia if it is not severe. Severe hemolytic anemia may be very quickly fatal and immediate hospitalization is required for transfusion of washed and packed red blood cells. Severe anemias can aggravate pre-existing heart disease, lung disease and cerebrovascular disease.

Frequently with cancer treatments, a patient may undergo numerous blood transfusions to accomodate for the severe anemia suffered as a result of chemotherapy. Researchers, investigating ways to enhance the quality of life for chemotherapy patients, have primarily looked at controlling pain and loss of appetite (anorexia). Recent studies, however, have examined the use of erythropoietin (a protein hormone that stimulates red blood cell production) in improving fatigue symptoms and enhancing overall quality of life. Once-weekly therapy with erythropoietin was found to increase hemoglobin levels, decrease transfusion requirements, and improve quality of life in patients with cancer and anemia undergoing chemotherapy.

Alternative and Complementary Therapies

Since there is no known prevention for hemolytic anemia, there is relatively little that can be done except to be aware of the risk factors and know the potential for genetic disorders within the family. Avoiding exposure to chemicals that precipitate the reaction, eating natural, whole grain foods, avoiding stress, and taking vitamin supplements can be helpful. With cancer patients, yoga and meditation provide a means of enhancing relaxation, reducing stress, and incorporating visualization for healing. Those patients who attend and participate in support groups have an increased quality of life with better outcomes from treatments.

Resources

Books

Jarvis, Carolyn. Physical Examination and Health Assessment. Philadelphia: W.B. Saunders Company, 2000.

Periodicals

Gabrilove, J.L., C.S. Cleeland, R.B. Livingston, et al. "Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients." Journal of Clinical Oncology 19 (2001): 2875–82.

Mantovani, L., G. Lentini, B. Hentschel, et al. "Treatment of Anaemia in Myelodysplastic Syndromes." British Journal of Haematology 109 (2000): 367–75.

Osoba, D. "Health-Related Quality-of-Life Assessment in Clinical Trials." Support Care Cancer 8 (2000): 84–8.

Parsons, S.K. "Hematopoietic Growth Factors for Children With Cancer." Current Opinions in Pediatrics 12 (2000): 10–7.

—Linda K. Bennington, C.N.S., M.S.N.

Mosby's Dental Dictionary:

hemolytic anemia

Top

n

An anemia characterized by an increased rate of destruction of red blood cells, reticulocytosis, hyperbilirubinemia, and/or increased urinary and fecal urobilinogen, and, generally, splenic enlargement. Hereditary hemolytic anemias include congenital hemolytic jaundice, sickle cell anemia, oval cell anemia, and thalassemia. Acquired hemolytic anemias include paroxysmal nocturnal hemoglobinuria and those caused by immune mechanisms (erythroblastosis fetalis), transfusions of incompatible blood, infections, drugs, and poisons. Autoimmune hemolytic anemias are acquired hemolytic anemias associated with antibody-like substances that may not be true autoantibodies or even antibodies; they may be primary (idio-pathic), or they may be secondary to lymphoma, lymphatic leukemia, disseminated lupus erythematosus, or sensitization to drugs and pollens.

Wikipedia on Answers.com:

Hemolytic anemia

Top
Hemolytic anemia
Classification and external resources
ICD-10 D55-D59
ICD-9 282, 283, 773
DiseasesDB 5534
MedlinePlus 000571
eMedicine med/979
MeSH D000743

Hemolytic anemia (or haemolytic anaemia) is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels (intravascular hemolysis) or elsewhere in the human body (extravascular). It has numerous possible causes, ranging from relatively harmless to life-threatening. The general classification of hemolytic anemia is either inherited or acquired. Treatment depends on the cause and nature of the breakdown.

Symptoms of hemolytic anemia are similar to other forms of anemia (fatigue and shortness of breath), but in addition, the breakdown of red cells leads to jaundice and increases the risk of particular long-term complications, such as gallstones and pulmonary hypertension.

Contents

Basic features

Hemolytic anemia involves the following:

  1. Abnormal and accelerated destruction of red cells and, in some anemias, their precursors
  2. Increased breakdown of hemoglobin, which may result in:
    1. increased bilirubin level (mainly indirect-reacting) with jaundice
    2. increased fecal and urinary urobilinogen
    3. Hemoglobinanemia, methemalbuminemia, hemoglobinuria and hemosiderinuria (where there is significant intravascular hemolysis).
  3. Bone marrow compensatory reaction:
    1. Erythroid hyperplasia with accelerated production of red cells, reflected by reticulocytosis, and slight macrocytosis in peripheral blood
    2. Expansion of bone marrow in infants and children with severe chronic hemolysis - changes in bone configuration visible on X-ray
  4. The balance between red cell destruction and marrow compensation determines the severity of anemias.

Signs and symptoms

In general, signs of anemia (pallor, fatigue, shortness of breath, and potential for heart failure) are present. In small children, failure to thrive may occur in any form of anemia. Certain aspects of the medical history can suggest a cause for hemolysis, such as drugs, consumption of fava beans, the presence of prosthetic heart valve, or other medical illness.

Chronic hemolysis leads to an increased excretion of bilirubin into the biliary tract, which in turn may lead to gallstones. The continuous release of free hemoglobin has been linked with the development of pulmonary hypertension (increased pressure over the pulmonary artery); this, in turn, leads to episodes of syncope (fainting), chest pain, and progressive breathlessness. Pulmonary hypertension eventually causes right ventricular heart failure, the symptoms of which are peripheral edema (fluid accumulation in the skin of the legs) and ascites (fluid accumulation in the abdominal cavity).

Causes

They may be classified according to the means of hemolysis, being either intrinsic in cases where the cause is related to the red blood cell (RBC) itself, or extrinsic in cases where factors external to the RBC dominate.[1] Intrinsic effects may include problems with RBC proteins or oxidative stress handling, whereas external factors include immune attack and microvascular angiopathies (RBCs are mechanically damaged in circulation).

Intrinsic causes

Hereditary (inherited) hemolytic anemia can be due to membrane defects:

Hereditary (inherited) hemolytic anemia can be due to defects in hemoglobin :

Hereditary (inherited) hemolytic anemia can be due to enzyme defects:

Acquired due to Paroxysmal nocturnal hemoglobinuria:

  • Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterized by complement-induced intravascular hemolytic anemia

Extrinsic causes

Acquired hemolytic anemia may be caused by immune-mediated causes, drugs and other miscellaneous causes.

Pathophysiology

In a healthy person, a red blood cell survives 90 to 120 days in the circulation, so about 1% of human red blood cells break down each day. The spleen (part of the reticulo-endothelial system) is the main organ that removes old and damaged RBCs from the circulation. In healthy individuals, the breakdown and removal of RBCs from the circulation is matched by the production of new RBCs in the bone marrow.

In conditions where the rate of RBC breakdown is increased, the body initially compensates by producing more RBCs; however, breakdown of RBCs can exceed the rate that the body can make RBCs, and so anemia can develop. Bilirubin, a breakdown product of hemoglobin, can accumulate in the blood, causing jaundice, and be excreted in the urine causing the urine to become a dark brown color.

In general, hemolytic anemia occurs as a modification of the RBC life cycle. That is, instead of being collected at the end of its useful life and disposed of normally, the RBC disintegrates in a manner allowing free iron-containing molecules to reach the blood. It is perhaps then helpful to understand the physiology of the RBC and things that can go wrong to cause it to "die" prematurely. With their complete lack of mitochondria, RBCs rely on glycolysis for the materials needed to reduce oxidative damage. Any limitations of glycolysis can result in more susceptibility to oxidative damage and a short or abnormal lifecycle. If the cell is unable to signal to the reticuloendothelial phagocytes by externalizing phosphatidylserine, it is likely to lyse through uncontrolled means.[4][5][6] Dogs and cats differ slightly from humans in some details of their RBC composition and have altered susceptibility to damage, notably, increased susceptibility to oxidative damage from onion or garlic.[7][8][9][10][11][12][13][14][15][16]

The distinguishing feature of intravascular hemolysis is the release of RBC contents into the blood stream. The metabolism and elimination of these products, largely iron-containing compounds capable of doing damage through Fenton reactions, is an important part of the condition. Several reference texts exist on the elimination pathways, for example.[17][18] Free hemoglobin can bind to haptoglobin, or it may oxidize and release the heme group that is able to bind to either albumin or hemopexin. The heme is ultimately converted to bilirubin and removed in stool and urine.[17] Hemoglobin may be cleared directly by the kidneys resulting in fast clearance of free hemoglobin but causing the continued loss of hemosiderin loaded renal tubular cells for many days.

Additional effects of free hemoglobin seem to be due to specific reactions with NO.[19]

Diagnosis

  • Peripheral blood smear microscopy:
    • fragments of the red blood cells ("schistocytes") can be present
    • some red blood cells may appear smaller and rounder than usual (spherocytes)
    • Reticulocytes are present in elevated numbers. This may be overlooked if a special stain is not used.
  • The level of unconjugated bilirubin in the blood is elevated. This may lead to jaundice.
  • The level of lactate dehydrogenase (LDH) in the blood is elevated
  • Haptoglobin levels are decreased
  • If the direct Coombs test is positive, hemolysis is caused by an immune process.
  • Hemosiderin in the urine indicates chronic intravascular hemolysis. There is also urobilinogen in the urine.

Treatment

Definitive therapy depends on the cause:

  • Symptomatic treatment can be given by blood transfusion, if there is marked anemia.
  • In severe immune-related hemolytic anemia, steroid therapy is sometimes necessary.
  • Sometimes splenectomy can be helpful where extravascular hemolysis is predominant (i.e. most of the red blood cells are being removed by the spleen).

Veterinary cases

Hemolytic anemia may affect non human species as well. It has been found in a number of animal species to result from specific triggers.[20]

Some notable cases include hemolytic anemia found in black rhinos kept in captivity, with the disease affecting 20% of the animals in one instance.[21][22][23] The disease is also found in wild rhinos.[24]

References

  1. ^ Current Medical Diagnosis and Treatment 2009 By Stephen J. McPhee, Maxine A. Papadakis page 436 http://books.google.com/books?id=zQlH4mXSziYC&pg=PT454&dq=hemoglobin+hemosiderin+hemolysis+bilirubin&ei=Z2P_SuzwA6D2ygT9vOz3Dg#v=onepage&q=hemoglobin%20hemosiderin%20hemolysis%20bilirubin&f=false
  2. ^ Telford RD, Sly GJ, Hahn AG, Cunningham RB, Bryant C, Smith JA (January 2003). "Footstrike is the major cause of hemolysis during running". J. Appl. Physiol. 94 (1): 38–42. doi:10.1152/japplphysiol.00631.2001. PMID 12391035. http://jap.physiology.org/cgi/content/full/94/1/38. 
  3. ^ Wise, Donald Lee (2000). Biomaterials Engineering and Devices: Orthopedic, dental, and bone graft applications. ISBN 9780896038592. http://books.google.com/?id=bJF2zgOhJcoC&pg=PA203&lpg=PA203&dq=Biomaterials+Engineering+and+Devices-Human+applications+D.L.Wise#v=onepage&q=Biomaterials%20Engineering%20and%20Devices-Human%20applications%20D.L.Wise&f=false. 
  4. ^ Kolb S, Vranckx R, Huisse MG, Michel JB, Meilhac O (July 2007). "The phosphatidylserine receptor mediates phagocytosis by vascular smooth muscle cells". The Journal of Pathology 212 (3): 249–59. doi:10.1002/path.2190. PMID 17534843. 
  5. ^ Bosman GJ, Willekens FL, Werre JM (2005). "Erythrocyte aging: a more than superficial resemblance to apoptosis?". Cellular Physiology and Biochemistry 16 (1–3): 1–8. doi:10.1159/000087725. PMID 16121027. 
  6. ^ Bratosin D, Mazurier J, Tissier JP, et al. (February 1998). "Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review". Biochimie 80 (2): 173–95. doi:10.1016/S0300-9084(98)80024-2. PMID 9587675. 
  7. ^ Chang HS, Yamato O, Sakai Y, Yamasaki M, Maede Y (January 2004). "Acceleration of superoxide generation in polymorphonuclear leukocytes and inhibition of platelet aggregation by alk(en)yl thiosulfates derived from onion and garlic in dogs and humans". Prostaglandins, Leukotrienes, and Essential Fatty Acids 70 (1): 77–83. doi:10.1016/j.plefa.2003.08.006. PMID 14643182. 
  8. ^ Yamato O, Hayashi M, Kasai E, Tajima M, Yamasaki M, Maede Y (April 1999). "Reduced glutathione accelerates the oxidative damage produced by sodium n-propylthiosulfate, one of the causative agents of onion-induced hemolytic anemia in dogs". Biochimica et Biophysica Acta 1427 (2): 175–82. doi:10.1016/S0304-4165(99)00023-9. PMID 10216234. 
  9. ^ Yamato O, Hayashi M, Yamasaki M, Maede Y (February 1998). "Induction of onion-induced haemolytic anemia in dogs with sodium n-propylthiosulphate". The Veterinary Record 142 (9): 216–9. doi:10.1136/vr.142.9.216. PMID 9533293. 
  10. ^ Yamoto O, Maede Y (January 1992). "Susceptibility to onion-induced hemolysis in dogs with hereditary high erythrocyte reduced glutathione and potassium concentrations". American Journal of Veterinary Research 53 (1): 134–7. PMID 1539905. 
  11. ^ Murase T, Maede Y (April 1990). "Increased erythrophagocytic activity of macrophages in dogs with Babesia gibsoni infection". Nippon Juigaku Zasshi 52 (2): 321–7. doi:10.1292/jvms1939.52.321. PMID 2348598. 
  12. ^ Ogawa E, Shinoki T, Akahori F, Masaoka T (August 1986). "Effect of onion ingestion on anti-oxidizing agents in dog erythrocytes". Nippon Juigaku Zasshi 48 (4): 685–91. doi:10.1292/jvms1939.48.685. PMID 3761777. 
  13. ^ Harvey JW, Rackear D (July 1985). "Experimental onion-induced hemolytic anemia in dogs". Veterinary Pathology 22 (4): 387–92. PMID 4035943. 
  14. ^ van Schouwenburg S (September 1982). "[Hemolytic anemia in a miniature dashshund caused by eating large amounts of onion (Allium cepa)]" (in Afrikaans). Journal of the South African Veterinary Association 53 (3): 212. PMID 7175912. 
  15. ^ Stallbaumer M (June 1981). "Onion poisoning in a dog". The Veterinary Record 108 (24): 523–4. doi:10.1136/vr.108.24.523. PMID 7257143. 
  16. ^ Spice RN (July 1976). "Hemolytic anemia associated with ingestion of onions in a dog". The Canadian Veterinary Journal. La Revue Vétérinaire Canadienne 17 (7): 181–3. PMC 1697286. PMID 949673. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1697286. 
  17. ^ a b Hematology in clinical practice: a guide to diagnosis and management By Robert S. Hillman, Kenneth A. Ault, Henry M. Rinder page 136-139 http://books.google.com/books?id=NJs1VpA8SEoC&pg=PA138&dq=hemoglobin+hemosiderin+hemolysis+bilirubin&ei=Z2P_SuzwA6D2ygT9vOz3Dg#v=onepage&q=hemoglobin%20hemosiderin%20hemolysis%20bilirubin&f=false
  18. ^ Wintrobe's Clinical Hematology, Volume 1 By John P. Greer http://books.google.com/books?id=68enzUD7BVgC&pg=PA161&dq=hemoglobin+hemosiderin+hemolysis+bilirubin&ei=Z2P_SuzwA6D2ygT9vOz3Dg#v=onepage&q=hemoglobin%20hemosiderin%20hemolysis%20bilirubin&f=false page 160
  19. ^ Boretti FS, Buehler PW, D'Agnillo F, et al. (August 2009). "Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs". The Journal of Clinical Investigation 119 (8): 2271–80. doi:10.1172/JCI39115. PMC 2719941. PMID 19620788. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2719941. 
  20. ^ Mary Anna Thrall, Dale C. Baker, E. Duane Lassen, Veterinary hematology and clinical chemistry, ISBN 0781768500, 2004.
  21. ^ Edward F. Gibbons, Barbara Susan Durrant, Jack Demarest, Conservation of endangered species in captivity: an interdisciplinary approach, page 324, 2005, ISBN 0791419118
  22. ^ Oliver A. Ryder, Zoological Society of San Diego, Rhinoceros biology and conservation, Zoological Society of San Diego, 1993, page 312, 335.
  23. ^ Texas Monthly, Oct 1992, Vol. 20, No. 10, ISSN 0148-7736, page 98-100.
  24. ^ Jutta Meister, ed. Catharine E. Bell, Encyclopedia of the world's zoos, Volume 3, page 1008, ISBN 1579581749, 2001.

 
 

 

Copyrights:

American Heritage Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
$copyright.smallImage.alttext Gale Encyclopedia of Cancer. Gale Encyclopedia of Cancer. Copyright © 2006 by The Gale Group, Inc. All rights reserved.  Read more
Mosby's Dental Dictionary. Mosby's Dental Dictionary. Copyright © 2004 by Elsevier, Inc. All rights reserved.  Read more
Wikipedia on Answers.com. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Hemolytic anemia Read more

Follow us
Facebook Twitter
YouTube